Julie Boerner
Office Address
816 HWCRC
4100 John R.
Detroit, MI 48201
Department
Oncology
Research Interests
- Role of c-Met in EGFR tyrosine kinase inhibitor resistance in breast cancer.
- Lipid raft localization of EGFR family members as a mechanism of resistance to EGFR inhibitors in breast cancer.
- Role of tyrosine 845 phosphorylation on EGFR on migration and transformation of breast cancer cells.
- Src regulation of Ras activity in pancreatic cancer.
Selected publications
Brock EJ, Jackson RM, Boerner JL, Li Q, Tennis MA, Sloane BF, Mattingly RR. Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma. PLoS One. 2021;16:e0252314.
Rumman M, Buck S, Polin L, Dzinic S, Boerner J, Winer IS. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity. Cancer Med. 2021;10:3373-87.
Shaik AN, Kiavash K, Stark K, Boerner JL, Ruterbusch JJ, Deirawan H, Bandyopadhyay S, Ali-Fehmi R, Dyson G, Cote ML. Inflammation markers on benign breast biopsy are associated with risk of invasive breast cancer in African American women. Breast Cancer Res Treat. 2021;185:831-9.
Purrington KS, Raychaudhuri S, Simon MS, Clark J, Ratliff V, Dyson G, Craig DB, Boerner JL, Beebe-Dimmer JL, Schwartz AG. Heritable Susceptibility to Breast Cancer among African-American Women in the Detroit Research on Cancer Survivors Study. Cancer Epidemiol Biomarkers Prev. 2020;29:2369-75.
Purrington KS, Knight J 3rd, Dyson G, Ali-Fehmi R, Schwartz AG, Boerner JL, Bandyopadhyay S. CLCA2 expression is associated with survival among African American women with triple negative breast cancer. PLoS One. 2020;15:e0231712.
Bao B, Teslow EA, Mitrea C, Boerner JL, Dyson G, Bollig-Fischer A. Role of TET1 and 5hmC in an Obesity-Linked Pathway Driving Cancer Stem Cells in Triple-Negative Breast Cancer. Mol Cancer Res. 2020;18:1803-14.
McKnight BN, Kim S, Boerner JL, Viola NT. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer. Breast Cancer Res. 2020;22:37.
Vaishampayan UN, Podgorski I, Heilbrun LK, Lawhorn-Crews JM, Dobson KC, Boerner J, Stark K, Smith DW, Heath EI, Fontana JA, Shields AF. Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res. 2019;25:652-62.
Education/Training
BS in Molecular Biology (1993): University of Wisconsin
MS in Endocrinology Reproductive-Physiology (1996): University of Wisconsin
PhD Tumor Biology (2000): Mayo Clinic
University of Virginia, post-doctoral fellowship with Dr. Sarah Parsons
Courses Taught
CB7300 F31 Grant Writing Course
CB7460 Mechanism of Neoplasia: Alterations to Cellular Signaling
CB7700 Recent Developments in Cancer Biology
CB7990 Research Technologies in Cancer Research